Dose-finding study of triptorelin acetate for prevention of a premature LHsurge in IVF: a prospective, randomized, double-blind, placebo-controlled study
Rmj. Janssens et al., Dose-finding study of triptorelin acetate for prevention of a premature LHsurge in IVF: a prospective, randomized, double-blind, placebo-controlled study, HUM REPR, 15(11), 2000, pp. 2333-2340
Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF
programmes to prevent an unwanted LH surge and consequent ovulation, Despit
e its widespread use in IVF, a convincing dose recommendation for GnRHa in
IVF does not exist. In our opinion, the lowest possible dose of GnRHa shoul
d be used. Thus, me performed a prospective, randomized, double-blind, plac
ebo-controlled study to determine the minimal daily dose of triptorelin ace
tate needed to suppress a premature LH surge during IVF treatment in a long
protocol. A total of 240 women (60 in each group) was randomized to either
placebo or to one of three doses of triptorelin, i.e. 15, 50 or 100 mug da
ily. Ovarian stimulation was performed with two or three ampoules of FSH da
ily. A premature LH surge occurred in 23% of placebo-treated patients, but
in none of the triptorelin acetate-treated patients. There were significant
ly more oocytes and embryos in the 50 and 100 mug triptorelin groups, There
was no dose relationship in rates of either implantation, pregnancy, ongoi
ng pregnancy, live birth or baby take-home. In this study we showed that da
ily administration of 15 mug triptorelin is sufficient to prevent a prematu
re LH surge, and that 50 mug is equivalent to 100 mug in terms of IVF resul
ts.